Innoviva Inc (INVA) 11.79 $INVA Keryx (KERX) Stock Down

New Post Public Reply Private Reply Replies (0) Message Board

Aug 21, 2016 at 3:11 AM

Innoviva Inc (INVA) 11.79 $INVA

Keryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:17AM CDT
Keryx (KERX) announced disruption in the supply of Auryxia tablets along with disappointing second-quarter results.
ZTS: 52.54 (+0.25), INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), KERX: 4.37 (-0.09)

Tired of Bargain Hunting? Bet on 6 Stocks with Rising P/E
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 6:46AM CDT
Forget undervalued stocks, stocks with rising P/E also offer upside potential.
ZFGN: 3.09 (-0.11), GT: 29.18 (+0.06), INVA: 11.79 (-0.18), TI: 9.02 (-0.17), FBR: 6.52 (+0.06), DAC: 3.65 (-0.15)

Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 52.54 (+0.25), INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), SNY: 39.67 (-0.09)

Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:06AM CDT
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
INVA: 11.79 (-0.18), FCSC: 1.02 (-0.01), ANIP: 67.99 (-1.00), ALKS: 44.39 (-0.86)

AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), AZN: 33.56 (-0.01), NKTR: 17.26 (-0.46)

Innoviva Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 3:05PM CDT
--U.S. TRx market share recently reached all-time highs of 10% for BREO and 8% for ANORO
INVA: 11.79 (-0.18)

Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 11:11AM CDT
Celgene (CELG) reported better-than-expected second-quarter 2016 earnings and revenues; it once again raised the earnings outlook for 2016.
INVA: 11.79 (-0.18), FCSC: 1.02 (-0.01), ANIP: 67.99 (-1.00), CELG: 112.16 (+0.03)

Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), ALXN: 132.13 (-0.30), NKTR: 17.26 (-0.46)

Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), GSK: 44.16 (-0.33), NVS: 81.34 (-0.60)

Bristol-Myers (BMY) Beats on Q2 Earnings, Lifts Outlook
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Bristol-Myers' (BMY) delivered better-than-expected second-quarter 2016 earnings and revenues; it raised the 2016 earnings outlook yet again.
INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00), PFE: 34.98 (-0.21), BMY: 59.29 (+0.61)

Bayer (BAYRY) Beats on Q2 Earnings, Updates 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:10AM CDT
Bayer's (BAYRY) second-quarter 2016 core earnings of $2.34 per share topped estimates while revenues marginally missed expectations; it revised its 2016 outlook.
MON: 104.15 (+0.16), INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00)

Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 316.81 (+3.43), INVA: 11.79 (-0.18), AMGN: 173.62 (-1.13), FMS: 44.68 (-1.74)

Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 316.81 (+3.43), VRTX: 98.01 (-1.09), INVA: 11.79 (-0.18), ANIP: 67.99 (-1.00)

Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.79 (-0.18), TBPH: 27.89 (-0.61), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61)

Technical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva
PR Newswire - Thu Jun 09, 8:05AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Fortinet Inc. (NASDAQ: FTNT), Workday Inc. (NYSE: WDAY), Proofpoint Inc. (NASDAQ: PFPT), and Innoviva Inc. (NASDAQ: INVA). Learn more about these stocks by accessing their free trade alerts at:
PFPT: 76.15 (+0.11), INVA: 11.79 (-0.18), WDAY: 82.08 (+0.71), FTNT: 34.90 (-0.17)

Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.79 (-0.18), TBPH: 27.89 (-0.61), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61)

Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.79 (-0.18), GSK: 44.16 (-0.33)

Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.79 (-0.18), GSK: 44.16 (-0.33)

Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.79 (-0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...